Human papillomavirus type 16 E5 protein as a therapeutic target

Yonsei Medical Journal

Volumn 47, Issue 1, 2006, Pages 1-14

  Kim, Sang Woo ^a   Yang, Joo Sung ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Cervical cancer; E5 protein; Papillomavirus; Therapeutic vaccine

Indexed keywords

GENE PRODUCT; HUMAN PAPILLOMAVIRUS TYPE 16 E5 PROTEIN; HUMAN PAPILLOMAVIRUS TYPE 16 E6 PROTEIN; HUMAN PAPILLOMAVIRUS TYPE 16 E7 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

ANTIGEN PRESENTATION; CANCER GROWTH; CANCER INVASION; CONDYLOMA; DISEASE COURSE; DRUG DESIGN; DRUG TARGETING; EARLY RESPONSE GENE; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MALIGNANT TRANSFORMATION; NONHUMAN; PATHOGENESIS; PRECANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS REPLICATION;

FEMALE; GENOME, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY, ACTIVE; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 33644805157     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.1.1     Document Type: Review

References (63)

1. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004; 55:319-31.
2. McMurray HR, Nguyen D, Westbrook TF, McAnce DJ. Biology of human papillomaviruses. Int J Exp Pathol 2001;82:15-33.
3. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004;68:362-72.
4. Struyk L, van der Meijden E, Minnaar R, Fontaine V, Meijer I, ter Schegget J. Transcriptional regulation of human papillomavirus type 16 LCR by different C/EBPbeta isoforms. Mol Carcinog 2000;28:42-50.
5. McBride AA, Romanczuk H, Howley PM. The papillomavirus E2 regulatory proteins. J Biol Chem 1991; 266:18411-4.
6. Heino P, Goldman S, Lagerstedt U, Dillner J. Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma. Int J Cancer 1993;53:377-81.
7. Chiang CM, Ustav M, Stenlund A, Ho TF, Broker TR, Chow LT. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci USA 1992;89:5799-803.
8. Chiang CM, Dong G, Broker TR, Chow LT. Control of human papillomavirus type 11 origin of replication by the E2 family of transcription regulatory proteins. J Virol 1992;66:5224-31.
9. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32 Suppl 1:S7-15.
10. Doorbar J, Ely S, Sterling J, McLean C, Crawford L. Specific interaction between HPV-16 E1-F4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991;352:824-7.
11. Davy CE, Jackson DJ, Raj K, Peh WL, Southern SA, Das P, et al. Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes. J Virol 2005;79:3998-4011
12. DiMaio D, Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 2001; 20:7866-73.
13. Genther Williams SM, Disbrow GL, Schlegel R, Lee D, Threadgill DW, et al. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a highrisk human papillomavirus oncogene. Cancer Res 2005; 65:6534-42.
14. Borzacchiello G, Russo V, Gentile F, Roperto F, Venuti A, Nitsch L, et al. Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours. Oncogene 2005.
15. Ishiji T. Molecular mechanism of carcinogenesis by human papillomavirus-16. J Dermatol 2000;27:73-86.
16. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989;8:3905-10.
17. Yasumoto S. HPV16 participates in progressive transformation of normal epidermal cells. Gan To Kagaku Ryoho 1989;16:549-61.
18. Kessis TD, Slebos RJ, Nelson WC, Kastan MB, Plunkett BS, Han SM, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90: 3988-92.
19. Jenison SA, Yu XP, Valentine JM, Galloway DA. Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common evitope. J Virol 1989;63:809-18.
20. Tsai TC, Chen SL. The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch Virol 2003;148:1445-53.
21. Oetke C, Auvinen E, Pawlita M, Alonso A. Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol 2000;145:2183-91.
22. Yang DH, Wildeman AG, Sharom FJ. Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16. Protein Expr Purif 2003;30:1-10.
23. Auvinen E, Alonso A, Auvinen P. Human papillomavirus type 16 E5 protein colocalizes with the antiapoptotic Bcl-2 protein. Arch Virol 2004;149:1745-59.
24. Rodriguez MI, Finbow ME, Alonso A. Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene 2000;19:3727-32.
25. Martin P, Vass WC, Schiller JT, Lowy DR, Velu TJ. The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptor. Cell 1989;59:21-32.
26. Petti L, Nilson LA, DiMaio D. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J 1991; 10:845-55.
27. Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005;24:2585-8.
28. Crusius K, Auvinen F, Alonso A. Enhancement of EGF-and l'MA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997;15:1437-44.
29. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995;69:3185-92.
30. Stoppler MC, Straight SW, Tsao G, Schlegel R, McCance DJ. The E5 gone of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 1996;223:251-4.
31. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulate the transforming activity of tile epidermal growth factor receptor. Oncogene 1992;7: 27-32.
32. Jin H, Wang J, Zuo Y. Expression of c-jun, c-fos and MDM2 mRNA in cultured kerotinocytes through transfecting HPV16. Zhonghua Yi Xue Za Zhi 2001;81:171-3.
33. Tsao YP, Li LY, Tsai TC, Chen SL. Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes. J Virol 1996;70:7535-9.
34. Hasegawa M, Ohoka I, Yamazaki K, Hanami K, Sugano I, Nagao T, et al. Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection. Pathol Int 2002;52: 442-50.
35. Hernadi Z, Gazdag L, Szoke K, Sapy T, Krasznai ZT, Konya J. Duration of HPV-associated risk for highgrade cervical intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol 2005, Oct 21, [Epub ahead of print].
36. Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996;13:427-31.
37. Wang Q, Griffin H, Southern S, Jackson D, Martin A, McIntosh P, et al. Functional analysis of the human papillomavirus type 16 E1-E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. J Virol 2004;78:821-33.
38. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994;91:5320-4.
39. Wang P, Peng Z, Wang H. Study on the carcinogenic mechanism of human papillomavirus type 16 E7 protein in cervical carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2000;14:117-20.
40. Huang FY, Kwok YK, Lau ET, Tang MH, Ng TY, Ngan HY. Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet 2005;157:42-8.
41. Bian J, Connolly DC, Hedrick L, Cho KR. Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1997;11:271-3.
42. Slebos RJ, Kessis TD, Chen AW, Han SM, Hedrick L, Cho KR. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. Virology 1995;208: 111-20.
43. Tamada Y. The biological activities of the human papillomavirus type 16 E6/E7 cDNAs cloned from the SiHa cervical carcinoma cell line. Hokkaido Igaku Zasshi 1993;68:849-61.
44. Angeline M, Merle F, Moroianu J. The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a nonclassical Ran-dependent pathway. Virology 2003;317:13-23.
45. Pastrana DV, Vass WC, Lowy DR, Schiller JT. HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001;279:361-9.
46. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999;73:9609-13.
47. Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, SchillerJT, Lowy DR, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005;23:3634-41.
48. Schiller JT, Lowy DR. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001;28:50-4.
49. Liu HL, Li WS, Lei T, Zheng J, Zhang Z, Yan XF, et al. Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta Biochim Biophys Sin (Shanghai) 2005;37:153-8.
50. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, et al Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128-37.
51. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 2005;10:528-38.
52. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 2001;290: 350-60.
53. Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T, et al. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 2005;12:1410-4.
54. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZO, Giles-Davis, W, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000;270:146-61.
55. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000;74:2888-94.
56. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-9.
57. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-8.
58. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA, et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121:216-25.
59. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-17.
60. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999;73:5402-10.
61. Gill DK, Bible JM, Biswas C, Kell B, Best JM, Punchard NA, et al. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia. J Gen Virol 1998;79:1971-6.
62. Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, et al. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 2000;74:9083-9.
63. Chen YF, Lin CW, Tsao YP, Chen SL. Cytotoxic-T lymphocyte human papillomavirus type 16 F5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004;78:1333-43.